Skip to main content

Advertisement

Log in

Economic Burden and Costs of Chronic Migraine

  • Chronic Daily Headache (SJ Wang, Section Editor)
  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Chronic migraine (CM) is a subtype of migraine broadly defined by the presence of headache at least 15 days per month. Emerging evidence suggests that CM and episodic migraine (EM) differ not only in headache frequency, but that they are distinct clinical entities. Because individuals with CM are more disabled, they demonstrate higher societal burden than those with EM. There have been three important surveys published within the last five years that have focused on the societal burden associated with CM. The first is the American Migraine Prevalence and Prevention (AMPP) study, a longitudinal population-based survey performed in the U.S. The second, the International Burden Migraine Study (IBMS), is a Web-based survey conducted in North America, Western Europe, Asia/Pacific, and Brazil. The third is a clinic-based survey performed in Taiwan. This review discusses results of these studies with regard to healthcare resource use (and related direct costs) and loss of productivity (and related indirect costs) from the perspective of cost-effectiveness of new therapeutic approaches to CM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache. 1987;27:102–6.

    Article  CAS  PubMed  Google Scholar 

  2. Silberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near daily headache. Proposed revisions to the IHS criteria. Headache. 1994;34:1–7.

    Article  Google Scholar 

  3. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised criteria. Neurology. 1996;47:871–5.

    Article  CAS  PubMed  Google Scholar 

  4. Headache Classification Committee; Olesen J, Bousser MG, Diener HC, et al. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24(suppl 1):9–160.

    Google Scholar 

  5. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26:1409–10.

    Article  CAS  PubMed  Google Scholar 

  6. •• Headache Classification Committee. The International Classification of Headache Disorders: 3rd edition beta version). Cephalalgia 2013;33:629–808. International Headache Society published in July 2013 the third edition of the International Classification of Headache Disorders (ICHD-3) with revised diagnostic criteria for chronic migraine. Clinicians and researchers should start using ICHD-3 criteria.

  7. Merikangas KR. Contributions of epidemiology to our understanding of migraine. Headache. 2013;53:230–46.

    Article  PubMed  Google Scholar 

  8. Natoli J, Manack A, Dean B, Butler Q, Turkel C, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30:599–609.

    CAS  PubMed  Google Scholar 

  9. Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15:70–8.

    Article  PubMed  Google Scholar 

  10. Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16:86–92.

    Article  PubMed Central  PubMed  Google Scholar 

  11. • Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD. Chronic migraine – classification, characteristics and treatment. Lancet Neurol. 2012;28:162–71. Diener and colleagues provide an excellent review on the evolution of our understanding of chronic migraine with focus on epidemiology pathophysiology, clinical features and treatment options.

    Google Scholar 

  12. Aurora SK, Dodick DW, Turkel CC, DeGryse R, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.

    Article  CAS  PubMed  Google Scholar 

  13. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse R, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–14.

    Article  CAS  PubMed  Google Scholar 

  14. Silberstein SD, Dodick DW, Saper J, Huh B, Slavin KV, Sharan A, et al. Cephalalgia. 2012;32:1165–79.

    Article  PubMed  Google Scholar 

  15. Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuses: a systematic review. Cephalalgia. 2011;31:837–50.

    Article  PubMed  Google Scholar 

  16. Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009;49:495–508.

    Article  Google Scholar 

  17. Payne KA, Varon SF, Kawata AK, Yeomans K, Wilcox TK, Manack A, et al. The International Burden of Migraine Study (IBMS): study design, methodology and baseline cohort characteristics. Cephalalgia. 2011;31:1116–30.

    Article  PubMed  Google Scholar 

  18. •• Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301–15. This article provides global results of IBMS in terms of healthcare resource use and lost productivity time related to chronic migraine.

    Article  CAS  PubMed  Google Scholar 

  19. •• Stokes MS, Werner JB, Lipton RB, Sullivan SD, Wilcox TK, Wells L, et al. Cost of health care among patients with chronic migraine and episodic migraine in Canada and the USA: Results from the International Burden of Migraine Study (IBMS). Headache. 2011;51:1058–77. This article provides detailed results of IBMS for North America (USA and Canada) in terms of costs of healthcare resource use related to chronic migraine.

    Article  PubMed  Google Scholar 

  20. •• Bloudek LM, Stokes M, Buse DC, Wilcox TTK, Lipton RB, Goadsby PJ, et al. Cost of healthcare for patients with migraine in five European countries: results of the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13:361–78. This article provides detailed results of IBMS for Western Europe (France, Germany, Italy, Spain UK) in terms of costs of healthcare resource use related to chronic migraine.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. •• Wang SJ, Wang PJ, Fuh JL, Peng KP, Ng K. Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: a clinic-based study in Taiwan. Cephalalgia. 2013;33:171–81. This clinic-based survey performed in Taiwan is the first to give detailed results about healthcare resource use and lost productivity time in Asia/Pacific region.

    Article  CAS  PubMed  Google Scholar 

  22. Buse DC, Lipton RB. Global perspectives on the burden of episodic and chronic migraine. Cephalalgia. 2013;33:885–90.

    Article  PubMed  Google Scholar 

  23. Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428–32.

    Article  CAS  PubMed  Google Scholar 

  24. Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB. Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med. 2010;52:8–14.

    Article  PubMed  Google Scholar 

  25. • Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW, et al. The cost-effectiveness of onabotulinumtoxin A for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ. 2013;16:877–87. This study focused on the prophylactic use of onabotulinumtoxin A is the first cost-effectiveness analysis for chronic migraine.

    Article  PubMed  Google Scholar 

  26. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–36.

    Article  PubMed  Google Scholar 

  27. Mueller O, Diener HC, Dammann P, Rabe K, Hagel V, Sure U, et al. Occipital nerve stimulation for intractable chronic cluster headache or migraine: a critical analysis of direct treatment costs and complications. Cephalalgia. 2013. doi:10.1177/0333102413493193.

    PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Dr. Michel Lanteri-Minet serves as a board member for Allergan, Lilly, Pfizer, and Astellas, and has received consultancies from Zambon, Boston Scientifics, UCB, and BMS. Dr. Lanteri-Minet received grants from Medtronic and Saint-Jude and payment for manuscript preparation from Medtronic and Reckitt Benckiser.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michel Lanteri-Minet.

Additional information

This article is part of the Topical Collection on Chronic Daily Headache

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lanteri-Minet, M. Economic Burden and Costs of Chronic Migraine. Curr Pain Headache Rep 18, 385 (2014). https://doi.org/10.1007/s11916-013-0385-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11916-013-0385-0

Keywords

Navigation